Outcome of lung transplant recipients infected with SARS-CoV-2/Omicron/B.1.1.529: a Nationwide German study

Kneidinger et al., Infection, doi:10.1007/s15010-022-01914-8

Sep 2022

Source PDF All Studies Meta AnalysisMeta

Retrospective 218 COVID+ lung transplant patients in Germany, showing no significant difference in severe cases with early molnupiravir use.

Potential risks of molnupiravir include the creation of dangerous variants, and mutagenicity, carcinogenicity, teratogenicity, and embryotoxicity1-10. Multiple analyses have identified variants potentially created by molnupiravir11-15.

Important missing comments or errors? Let us know.

Study covers remdesivir, casirivimab/imdevimab, sotrovimab, and molnupiravir.

risk of severe case, 15.1% higher, RR 1.15, p = 0.71, treatment 8 of 46 (17.4%), control 26 of 172 (15.1%).

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

1. Swanstrom et al., Lethal mutagenesis as an antiviral strategy, Science, doi:10.1126/science.abn0048.science.org, doi.org.

2. Hadj Hassine et al., Lethal Mutagenesis of RNA Viruses and Approved Drugs with Antiviral Mutagenic Activity, Viruses, doi:10.3390/v14040841.mdpi.com, doi.org.

3. Waters et al., Human genetic risk of treatment with antiviral nucleoside analog drugs that induce lethal mutagenesis: the special case of molnupiravir, Environmental and Molecular Mutagenesis, doi:10.1002/em.22471.wiley.com, doi.org.

4. Huntsman, M., An assessment of the reproductive toxicity of the anti-COVID-19 drug molnupiravir using stem cell-based embryo models, Master's Thesis, scholarspace.manoa.hawaii.edu/items/cd11342c-b4dc-44c0-8b44-ce6e3369c40b.hawaii.edu.

5. Zibat et al., N4-hydroxycytidine, the active compound of Molnupiravir, promotes SARS-CoV-2 mutagenesis and escape from a neutralizing nanobody, iScience, doi:10.1016/j.isci.2023.107786.sciencedirect.com, doi.org.

6. Shiraki et al., Convenient screening of the reproductive toxicity of favipiravir and antiviral drugs in Caenorhabditis elegans, Heliyon, doi:10.1016/j.heliyon.2024.e35331.sciencedirect.com, doi.org.

7. Gruber et al., Molnupiravir increases SARS‐CoV‐2 genome diversity and complexity: A case‐control cohort study, Journal of Medical Virology, doi:10.1002/jmv.29642.wiley.com, doi.org.

8. Marikawa et al., An active metabolite of the anti-COVID-19 drug molnupiravir impairs mouse preimplantation embryos at clinically relevant concentrations, Reproductive Toxicology, doi:10.1016/j.reprotox.2023.108475.sciencedirect.com, doi.org.

9. Zhou et al., β-D-N4-hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells, The Journal of Infectious Diseases, doi:10.1093/infdis/jiab247.oup.com, doi.org.

10. Chamod et al., Molnupiravir Metabolite--N4-hydroxycytidine Causes Cytotoxicity and DNA Damage in Mammalian Cells in vitro: N4-hydroxycytidine Induced Cytotoxicity DNA Damage, Asian Medical Journal and Alternative Medicine, 23:3, asianmedjam.com/index.php/amjam/article/view/1448.asianmedjam.com.

11. Focosi et al., The fitness of molnupiravir-signed SARS-CoV-2 variants: imputation analysis based on prescription counts and GISAID analyses by country, Intervirology, doi:10.1159/000540282.karger.com, doi.org.

12. Sanderson et al., A molnupiravir-associated mutational signature in global SARS-CoV-2 genomes, Nature, doi:10.1038/s41586-023-06649-6.nature.com, doi.org.

13. Fountain-Jones et al., Effect of molnupiravir on SARS-CoV-2 evolution in immunocompromised patients: a retrospective observational study, The Lancet Microbe, doi:10.1016/S2666-5247(23)00393-2.sciencedirect.com, doi.org.

14. Kosakovsky Pond et al., Anti-COVID drug accelerates viral evolution, Nature, doi:10.1038/d41586-023-03248-3.nature.com, doi.org.

15. twitter.com, twitter.com/LongDesertTrain/status/1597353291868155906.twitter.com/LongDesertTrain/status/1597353291868155906.

Kneidinger et al., 9 Sep 2022, retrospective, Germany, peer-reviewed, 11 authors, study period 1 January, 2022 - 20 March, 2022, lung transplant patients. Contact: nikolaus.kneidinger@med.uni-muenchen.de.

This Paper Molnupiravir All

Outcome of lung transplant recipients infected with SARS-CoV-2/Omicron/B.1.1.529: a Nationwide German study

Nikolaus Kneidinger, Matthias Hecker, Vasiliki Bessa, Ina Hettich, Alexandra Wald, Sabine Wege, Anna-Barbara Nolde, Maike Oldigs, Zulfiya Syunyaeva, Heinrike Wilkens, Jens Gottlieb

Infection, doi:10.1007/s15010-022-01914-8

Purpose Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) is currently the major threat for immunocompromised individuals. The course of COVID-19 in lung transplant recipients in the Omicron era remains unknown. The aim of the study was to assess outcome and associated factors in lung transplant recipients in a German-wide multicenter approach. Methods All affected individuals from January 1st to March 20th, 2022 from 8 German centers during the Omicron wave were collected. Baseline characteristics and antiviral measures were associated with outcome. Results Of 218 patients with PCR-proven SARS-CoV-2 infection 166 patients (76%) received any early (< 7 days) antiviral therapy median 2 (interquartile range 1-4) days after symptom onset. Most patients received sotrovimab (57%), followed by remdesivir (21%) and molnupiravir (21%). An early combination therapy was applied in 45 patients (21%). Thirty-four patients (16%) developed a severe or critical disease severity according to the WHO scale. In total, 14 patients (6.4%) died subsequently associated with COVID-19. Neither vaccination and antibody status, nor applied treatments were associated with outcome. Only age and glomerular filtration rate < 30 ml/min/1.73m 2 were independent risk factors for a severe or critical COVID-19. Conclusion COVID-19 due to Omicron remains an important threat for lung transplant recipients. In particular, elderly patients and patients with impaired kidney function are at risk for worse outcome. Prophylaxis and therapy in highly immunocompromised individuals need further improvement.

Author contributions NK and JG designed and directed the project. All authors contributed to the data collection. NK and JG performed the analysis and drafted the manuscript. All authors were involved in interpretation of results reviewed the manuscript. Funding Open Access funding enabled and organized by Projekt DEAL. Not applicable. Declarations Competing interests The authors declare no competing interests. Conflict of interest The authors have no competing interests as defined by Springer, or other interests that might be perceived to influence the results and/or discussion reported in this paper. Ethical approval The study was approved by the central institutional ethics committee (LMU Munich, Germany; project number 22-0078). Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the..

References

Aversa, Benvenuto, Anderson, COVID-19 in lung transplant recipients: a single center case series from New York City, Am J Transplant, doi:10.1111/ajt.16241

Bernal, Da Silva, Musungaie, Molnupiravir for oral treatment of covid-19 in nonhospitalized patients, N Engl J Med, doi:10.1056/NEJMoa2116044

Bouzid, Visseaux, Kassasseya, Comparison of patients infected with delta versus omicron COVID-19 variants presenting to paris emergency departments: a retrospective cohort study, Ann Intern Med, doi:10.7326/M22-0308

Coll, Fernández-Ruiz, Sánchez-Álvarez, COVID-19 in transplant recipients: the Spanish experience, Am J Transplant, doi:10.1111/ajt.16369

Fall, Eldesouki, Sachithanandham, variant delta with omicron: unprecedented spike in COVID-19 cases associated with fewer admissions and comparable upper respiratory viral loads, doi:10.1101/2022.01.26.22269927

Gleeson, Martin, Thomson, Kidney transplant recipients and omicron: outcomes, effect of vaccines and the efficacy and safety of novel treatments, medRxiv, doi:10.1101/2022.05.03.22274524

Gottlieb, Kolditz, Gade, Welte, Kneidinger, Benefit of monoclonal antibodies in early treatment of COVID-19 after lung transplantation-a retrospective analysis in two centers, Eur Respir J, doi:10.1183/13993003.00124-2022

Gottlieb, Vaca, Paredes, Early remdesivir to prevent progression to severe covid-19 in outpatients, N Engl J Med, doi:10.1056/NEJMoa2116846

Gupta, Gonzalez-Rojas, Juarez, Early treatment for covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab, N Engl J Med, doi:10.1056/NEJMoa2107934

Gupta, Gonzalez-Rojas, Juarez, Effect of sotrovimab on hospitalization or death among high-risk patients with mild to moderate COVID-19: a randomized clinical trial, JAMA, doi:10.1001/jama.2022.2832

Hadi, Naqvi, Kupec, Sofka, Sarwari, Outcomes of COVID-19 in solid organ transplant recipients: a propensitymatched analysis of a large research network, Transplantation, doi:10.1097/TP.0000000000003670

Havlin, Skotnicova, Dvorackova, Impaired humoral response to third dose of BNT162b2 mRNA COVID-19 vaccine despite detectable spike protein-specific T cells in lung transplant recipients, Transplantation, doi:10.1097/TP.0000000000004021

Havlin, Svorcova, Dvorackova, Immunogenicity of BNT162b2 mRNA COVID-19 vaccine and SARS-CoV-2 infection in lung transplant recipients, J Heart Lung Transplant, doi:10.1016/j.healun.2021.05.004

Heldman, Kates, Safa, Changing trends in mortality among solid organ transplant recipients hospitalized for COVID-19 during the course of the pandemic, Am J Transplant, doi:10.1111/ajt.16840

Hoffmann, Krüger, Schulz, The Omicron variant is highly resistant against antibody-mediated neutralization: implications for control of the COVID-19 pandemic, Cell, doi:10.1016/j.cell.2021.12.032

Hui, Ho, Cheung, Omicron variant replication in human bronchus and lung ex vivo, Nature, doi:10.1038/s41586-022-04479-6

Iketani, Liu, Guo, Antibody evasion properties of SARS-CoV-2 Omicron sublineages, Nature, doi:10.1038/s41586-022-04594-4

Kamp, Hinrichs, Fuge, Ewen, Gottlieb, COVID-19 in lung transplant recipients-risk prediction and outcomes, PLoS One, doi:10.1371/journal.pone.0257807

Koczulla, Sczepanski, Koteczki, SARS-CoV-2 infection in two patients following recent lung transplantation, Am J Transplant, doi:10.1111/ajt.15998

Maslo, Friedland, Toubkin, Characteristics and outcomes of hospitalized patients in South Africa during the COVID-19 omicron wave compared with previous waves, JAMA, doi:10.1001/jama.2021.24868

Pulliam, Van Schalkwyk, Govender, Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa, Science, doi:10.1126/science.abn4947

Ravanan, Mumford, Ushiro-Lumb, Two doses of SARS-CoV-2 vaccines reduce risk of death due to COVID-19 in solid organ transplant recipients: preliminary outcomes from a UK registry linkage analysis, Transplantation, doi:10.1097/TP.0000000000003908

Salerno, Jennings, Lange, Kovac, Shertel et al., Early clinical experience with nirmatrelvir/ritonavir for the treatment of COVID-19 in solid organ transplant recipients, Am J Transplant, doi:10.1111/ajt.17027

Takashita, Kinoshita, Yamayoshi, Efficacy of antiviral agents against the SARS-CoV-2 omicron subvariant BA.2, N Engl J Med, doi:10.1056/NEJMc2201933

Uraki, Kiso, Iida, Characterization and antiviral susceptibility of SARS-CoV-2 Omicron/BA, Nature, doi:10.1038/s41586-022-04856-1

Verleden, Glanville, Lease, Chronic lung allograft dysfunction: definition, diagnostic criteria, and approaches to treatment-a consensus report from the pulmonary council of the ISHLT, J Heart Lung Transplant, doi:10.1016/j.healun.2019.03.009

Wolter, Jassat, Walaza, Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study, Lancet, doi:10.1016/S0140-6736(22)00017-4

Wratil, Stern, Priller, Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern, Nat Med, doi:10.1038/s41591-022-01715-4

Wu, Mcgoogan, Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the chinese center for disease control and prevention, JAMA, doi:10.1001/jama.2020.2648

{ 'indexed': {'date-parts': [[2022, 9, 9]], 'date-time': '2022-09-09T13:14:24Z', 'timestamp': 1662729264827}, 'reference-count': 29, 'publisher': 'Springer Science and Business Media LLC', 'license': [ { 'start': { 'date-parts': [[2022, 9, 9]], 'date-time': '2022-09-09T00:00:00Z', 'timestamp': 1662681600000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by/4.0'}, { 'start': { 'date-parts': [[2022, 9, 9]], 'date-time': '2022-09-09T00:00:00Z', 'timestamp': 1662681600000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by/4.0'}], 'funder': [{'name': 'Universitätsklinik München'}], 'content-domain': {'domain': ['link.springer.com'], 'crossmark-restriction': False}, 'abstract': 'Abstract\n' ' Purpose\n' ' Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory ' 'syndrome coronavirus type 2 (SARS-CoV-2) is currently the major threat for immunocompromised ' 'individuals. The course of COVID-19 in lung transplant recipients in the Omicron era remains ' 'unknown. The aim of the study was to assess outcome and associated factors in lung transplant ' 'recipients in a German-wide multicenter approach.\n' ' \n' ' Methods\n' ' All affected individuals from January 1st to March 20th, 2022 from 8 ' 'German centers during the Omicron wave were collected. Baseline characteristics and antiviral ' 'measures were associated with outcome.\n' ' \n' ' Results\n' ' Of 218 patients with PCR-proven SARS-CoV-2 infection 166 patients (76%) ' 'received any early (<\u20097\xa0days) antiviral therapy median 2 (interquartile range 1–4) ' 'days after symptom onset. Most patients received sotrovimab (57%), followed by remdesivir ' '(21%) and molnupiravir (21%). An early combination therapy was applied in 45 patients (21%). ' 'Thirty-four patients (16%) developed a severe or critical disease severity according to the ' 'WHO scale. In total, 14 patients (6.4%) died subsequently associated with COVID-19. Neither ' 'vaccination and antibody status, nor applied treatments were associated with outcome. Only ' 'age and glomerular filtration rate\u2009<\u200930\xa0ml/min/1.73m2 ' 'were independent risk factors for a severe or critical COVID-19.\n' ' \n' ' Conclusion\n' ' COVID-19 due to Omicron remains an important threat for lung transplant ' 'recipients. In particular, elderly patients and patients with impaired kidney function are at ' 'risk for worse outcome. Prophylaxis and therapy in highly immunocompromised individuals need ' 'further improvement.\n' ' ', 'DOI': '10.1007/s15010-022-01914-8', 'type': 'journal-article', 'created': {'date-parts': [[2022, 9, 9]], 'date-time': '2022-09-09T12:37:36Z', 'timestamp': 1662727056000}, 'update-policy': 'http://dx.doi.org/10.1007/springer_crossmark_policy', 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'Outcome of lung transplant recipients infected with SARS-CoV-2/Omicron/B.1.1.529: a Nationwide ' 'German study', 'prefix': '10.1007', 'author': [ {'given': 'Nikolaus', 'family': 'Kneidinger', 'sequence': 'first', 'affiliation': []}, {'given': 'Matthias', 'family': 'Hecker', 'sequence': 'additional', 'affiliation': []}, {'given': 'Vasiliki', 'family': 'Bessa', 'sequence': 'additional', 'affiliation': []}, {'given': 'Ina', 'family': 'Hettich', 'sequence': 'additional', 'affiliation': []}, {'given': 'Alexandra', 'family': 'Wald', 'sequence': 'additional', 'affiliation': []}, {'given': 'Sabine', 'family': 'Wege', 'sequence': 'additional', 'affiliation': []}, {'given': 'Anna-Barbara', 'family': 'Nolde', 'sequence': 'additional', 'affiliation': []}, {'given': 'Maike', 'family': 'Oldigs', 'sequence': 'additional', 'affiliation': []}, {'given': 'Zulfiya', 'family': 'Syunyaeva', 'sequence': 'additional', 'affiliation': []}, {'given': 'Heinrike', 'family': 'Wilkens', 'sequence': 'additional', 'affiliation': []}, {'given': 'Jens', 'family': 'Gottlieb', 'sequence': 'additional', 'affiliation': []}], 'member': '297', 'published-online': {'date-parts': [[2022, 9, 9]]}, 'reference': [ { 'key': '1914_CR1', 'doi-asserted-by': 'publisher', 'first-page': '1825', 'DOI': '10.1111/ajt.16369', 'volume': '21', 'author': 'E Coll', 'year': '2021', 'unstructured': 'Coll E, Fernández-Ruiz M, Sánchez-Álvarez JE, et al. COVID-19 in ' 'transplant recipients: the Spanish experience. Am J Transplant. ' '2021;21:1825–37. https://doi.org/10.1111/ajt.16369.', 'journal-title': 'Am J Transplant'}, { 'key': '1914_CR2', 'doi-asserted-by': 'publisher', 'first-page': '2928', 'DOI': '10.1111/ajt.15998', 'volume': '20', 'author': 'RA Koczulla', 'year': '2020', 'unstructured': 'Koczulla RA, Sczepanski B, Koteczki A, et al. SARS-CoV-2 infection in ' 'two patients following recent lung transplantation. Am J Transplant. ' '2020;20:2928–32. https://doi.org/10.1111/ajt.15998.', 'journal-title': 'Am J Transplant'}, { 'key': '1914_CR3', 'doi-asserted-by': 'publisher', 'first-page': '3072', 'DOI': '10.1111/ajt.16241', 'volume': '20', 'author': 'M Aversa', 'year': '2020', 'unstructured': 'Aversa M, Benvenuto L, Anderson M, et al. COVID-19 in lung transplant ' 'recipients: a single center case series from New York City. Am J ' 'Transplant. 2020;20:3072–80. https://doi.org/10.1111/ajt.16241.', 'journal-title': 'Am J Transplant'}, { 'key': '1914_CR4', 'doi-asserted-by': 'publisher', 'DOI': '10.1371/journal.pone.0257807', 'volume': '16', 'author': 'JC Kamp', 'year': '2021', 'unstructured': 'Kamp JC, Hinrichs JB, Fuge J, Ewen R, Gottlieb J. COVID-19 in lung ' 'transplant recipients—risk prediction and outcomes. PLoS One. 2021;16: ' 'e0257807. https://doi.org/10.1371/journal.pone.0257807.', 'journal-title': 'PLoS One'}, { 'key': '1914_CR5', 'doi-asserted-by': 'publisher', 'first-page': '279', 'DOI': '10.1111/ajt.16840', 'volume': '22', 'author': 'MR Heldman', 'year': '2022', 'unstructured': 'Heldman MR, Kates OS, Safa K, et al. Changing trends in mortality among ' 'solid organ transplant recipients hospitalized for COVID-19 during the ' 'course of the pandemic. Am J Transplant. 2022;22:279–88. ' 'https://doi.org/10.1111/ajt.16840.', 'journal-title': 'Am J Transplant'}, { 'key': '1914_CR6', 'doi-asserted-by': 'publisher', 'first-page': 'e263', 'DOI': '10.1097/TP.0000000000003908', 'volume': '105', 'author': 'R Ravanan', 'year': '2021', 'unstructured': 'Ravanan R, Mumford L, Ushiro-Lumb I, et al. Two doses of SARS-CoV-2 ' 'vaccines reduce risk of death due to COVID-19 in solid organ transplant ' 'recipients: preliminary outcomes from a UK registry linkage analysis. ' 'Transplantation. 2021;105:e263–4. ' 'https://doi.org/10.1097/TP.0000000000003908.', 'journal-title': 'Transplantation'}, { 'key': '1914_CR7', 'doi-asserted-by': 'publisher', 'author': 'J Gottlieb', 'year': '2022', 'unstructured': 'Gottlieb J, Kolditz M, Gade N, Welte T, Kneidinger N. Benefit of ' 'monoclonal antibodies in early treatment of COVID-19 after lung ' 'transplantation—a retrospective analysis in two centers. Eur Respir J. ' '2022. https://doi.org/10.1183/13993003.00124-2022.', 'journal-title': 'Eur Respir J.', 'DOI': '10.1183/13993003.00124-2022'}, { 'key': '1914_CR8', 'doi-asserted-by': 'publisher', 'author': 'JRC Pulliam', 'year': '2022', 'unstructured': 'Pulliam JRC, van Schalkwyk C, Govender N, et al. Increased risk of ' 'SARS-CoV-2 reinfection associated with emergence of Omicron in South ' 'Africa. Science. 2022. https://doi.org/10.1126/science.abn4947.', 'journal-title': 'Science.', 'DOI': '10.1126/science.abn4947'}, { 'key': '1914_CR9', 'doi-asserted-by': 'publisher', 'first-page': '447', 'DOI': '10.1016/j.cell.2021.12.032', 'volume': '185', 'author': 'M Hoffmann', 'year': '2022', 'unstructured': 'Hoffmann M, Krüger N, Schulz S, et al. The Omicron variant is highly ' 'resistant against antibody-mediated neutralization: implications for ' 'control of the COVID-19 pandemic. Cell. 2022;185:447-456.e11. ' 'https://doi.org/10.1016/j.cell.2021.12.032.', 'journal-title': 'Cell.'}, { 'key': '1914_CR10', 'doi-asserted-by': 'publisher', 'first-page': '715', 'DOI': '10.1038/s41586-022-04479-6', 'volume': '603', 'author': 'KPY Hui', 'year': '2022', 'unstructured': 'Hui KPY, Ho JCW, Cheung MC, et al. Omicron variant replication in human ' 'bronchus and lung ex vivo. Nature. 2022;603:715–20. ' 'https://doi.org/10.1038/s41586-022-04479-6.', 'journal-title': 'Nature.'}, { 'key': '1914_CR11', 'doi-asserted-by': 'publisher', 'first-page': '437', 'DOI': '10.1016/S0140-6736(22)00017-4', 'volume': '399', 'author': 'N Wolter', 'year': '2022', 'unstructured': 'Wolter N, Jassat W, Walaza S, et al. Early assessment of the clinical ' 'severity of the SARS-CoV-2 omicron variant in South Africa: a data ' 'linkage study. Lancet. 2022;399:437–46. ' 'https://doi.org/10.1016/S0140-6736(22)00017-4.', 'journal-title': 'Lancet.'}, { 'key': '1914_CR12', 'doi-asserted-by': 'publisher', 'unstructured': 'Fall A, Eldesouki RE, Sachithanandham J, et al. A quick displacement of ' 'the SARS-CoV-2 variant delta with omicron: unprecedented spike in ' 'COVID-19 cases associated with fewer admissions and comparable upper ' 'respiratory viral loads. medRxiv. 2022. ' 'https://doi.org/10.1101/2022.01.26.22269927', 'DOI': '10.1101/2022.01.26.22269927'}, { 'key': '1914_CR13', 'doi-asserted-by': 'publisher', 'first-page': '1941', 'DOI': '10.1056/NEJMoa2107934', 'volume': '385', 'author': 'A Gupta', 'year': '2021', 'unstructured': 'Gupta A, Gonzalez-Rojas Y, Juarez E, et al. Early treatment for covid-19 ' 'with SARS-CoV-2 neutralizing antibody sotrovimab. N Engl J Med. ' '2021;385:1941–50. https://doi.org/10.1056/NEJMoa2107934.', 'journal-title': 'N Engl J Med.'}, { 'key': '1914_CR14', 'doi-asserted-by': 'publisher', 'first-page': '1236', 'DOI': '10.1001/jama.2022.2832', 'volume': '327', 'author': 'A Gupta', 'year': '2022', 'unstructured': 'Gupta A, Gonzalez-Rojas Y, Juarez E, et al. Effect of sotrovimab on ' 'hospitalization or death among high-risk patients with mild to moderate ' 'COVID-19: a randomized clinical trial. JAMA. 2022;327:1236–46. ' 'https://doi.org/10.1001/jama.2022.2832.', 'journal-title': 'JAMA.'}, { 'key': '1914_CR15', 'doi-asserted-by': 'publisher', 'unstructured': 'Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al. Molnupiravir for ' 'oral treatment of covid-19 in nonhospitalized patients. N Engl J Med. ' '2022;386(6):509–520. https://doi.org/10.1056/NEJMoa2116044', 'DOI': '10.1056/NEJMoa2116044'}, { 'issue': '3', 'key': '1914_CR16', 'doi-asserted-by': 'publisher', 'first-page': '496', 'DOI': '10.1038/s41591-022-01715-4', 'volume': '28', 'author': 'PR Wratil', 'year': '2022', 'unstructured': 'Wratil PR, Stern M, Priller A, et al. Three exposures to the spike ' 'protein of SARS-CoV-2 by either infection or vaccination elicit superior ' 'neutralizing immunity to all variants of concern. Nat Med. ' '2022;28(3):496–503. https://doi.org/10.1038/s41591-022-01715-4.', 'journal-title': 'Nat Med.'}, { 'key': '1914_CR17', 'doi-asserted-by': 'publisher', 'first-page': '493', 'DOI': '10.1016/j.healun.2019.03.009', 'volume': '38', 'author': 'GM Verleden', 'year': '2019', 'unstructured': 'Verleden GM, Glanville AR, Lease ED, et al. Chronic lung allograft ' 'dysfunction: definition, diagnostic criteria, and approaches to ' 'treatment—a consensus report from the pulmonary council of the ISHLT. J ' 'Heart Lung Transplant. 2019;38:493–503. ' 'https://doi.org/10.1016/j.healun.2019.03.009.', 'journal-title': 'J Heart Lung Transplant.'}, { 'key': '1914_CR18', 'doi-asserted-by': 'publisher', 'first-page': '1239', 'DOI': '10.1001/jama.2020.2648', 'volume': '323', 'author': 'Z Wu', 'year': '2020', 'unstructured': 'Wu Z, McGoogan JM. Characteristics of and important lessons from the ' 'coronavirus disease 2019 (COVID-19) outbreak in China: summary of a ' 'report of 72 314 cases from the chinese center for disease control and ' 'prevention. JAMA. 2020;323:1239–42. ' 'https://doi.org/10.1001/jama.2020.2648.', 'journal-title': 'JAMA.'}, { 'key': '1914_CR19', 'doi-asserted-by': 'publisher', 'author': 'D Bouzid', 'year': '2022', 'unstructured': 'Bouzid D, Visseaux B, Kassasseya C, et al. Comparison of patients ' 'infected with delta versus omicron COVID-19 variants presenting to paris ' 'emergency departments: a retrospective cohort study. Ann Intern Med. ' '2022. https://doi.org/10.7326/M22-0308.', 'journal-title': 'Ann Intern Med.', 'DOI': '10.7326/M22-0308'}, { 'key': '1914_CR20', 'doi-asserted-by': 'publisher', 'first-page': '583', 'DOI': '10.1001/jama.2021.24868', 'volume': '327', 'author': 'C Maslo', 'year': '2022', 'unstructured': 'Maslo C, Friedland R, Toubkin M, et al. Characteristics and outcomes of ' 'hospitalized patients in South Africa during the COVID-19 omicron wave ' 'compared with previous waves. JAMA. 2022;327:583–4. ' 'https://doi.org/10.1001/jama.2021.24868.', 'journal-title': 'JAMA.'}, { 'key': '1914_CR21', 'doi-asserted-by': 'publisher', 'first-page': 'e183', 'DOI': '10.1097/TP.0000000000004021', 'volume': '106', 'author': 'J Havlin', 'year': '2022', 'unstructured': 'Havlin J, Skotnicova A, Dvorackova E, et al. Impaired humoral response ' 'to third dose of BNT162b2 mRNA COVID-19 vaccine despite detectable spike ' 'protein-specific T cells in lung transplant recipients. Transplantation. ' '2022;106:e183–4. https://doi.org/10.1097/TP.0000000000004021.', 'journal-title': 'Transplantation.'}, { 'key': '1914_CR22', 'doi-asserted-by': 'publisher', 'first-page': '754', 'DOI': '10.1016/j.healun.2021.05.004', 'volume': '40', 'author': 'J Havlin', 'year': '2021', 'unstructured': 'Havlin J, Svorcova M, Dvorackova E, et al. Immunogenicity of BNT162b2 ' 'mRNA COVID-19 vaccine and SARS-CoV-2 infection in lung transplant ' 'recipients. J Heart Lung Transplant. 2021;40:754–8. ' 'https://doi.org/10.1016/j.healun.2021.05.004.', 'journal-title': 'J Heart Lung Transplant.'}, { 'key': '1914_CR23', 'doi-asserted-by': 'publisher', 'first-page': '305', 'DOI': '10.1056/NEJMoa2116846', 'volume': '386', 'author': 'RL Gottlieb', 'year': '2022', 'unstructured': 'Gottlieb RL, Vaca CE, Paredes R, et al. Early remdesivir to prevent ' 'progression to severe covid-19 in outpatients. N Engl J Med. ' '2022;386:305–15. https://doi.org/10.1056/NEJMoa2116846.', 'journal-title': 'N Engl J Med.'}, { 'key': '1914_CR24', 'doi-asserted-by': 'publisher', 'author': 'DM Salerno', 'year': '2022', 'unstructured': 'Salerno DM, Jennings DL, Lange NW, Kovac DB, Shertel T, Chen JK, Hedvat ' 'J, Scheffert J, Brown RS Jr, Pereira MR. Early clinical experience with ' 'nirmatrelvir/ritonavir for the treatment of COVID-19 in solid organ ' 'transplant recipients. Am J Transplant. 2022. ' 'https://doi.org/10.1111/ajt.17027.', 'journal-title': 'Am J Transplant.', 'DOI': '10.1111/ajt.17027'}, { 'key': '1914_CR25', 'doi-asserted-by': 'publisher', 'unstructured': 'Gleeson S, Martin P, Thomson T, et al. Kidney transplant recipients and ' 'omicron: outcomes, effect of vaccines and the efficacy and safety of ' 'novel treatments. medRxiv. https://doi.org/10.1101/2022.05.03.22274524', 'DOI': '10.1101/2022.05.03.22274524'}, { 'key': '1914_CR26', 'doi-asserted-by': 'publisher', 'first-page': '553', 'DOI': '10.1038/s41586-022-04594-4', 'volume': '604', 'author': 'S Iketani', 'year': '2022', 'unstructured': 'Iketani S, Liu L, Guo Y, et al. Antibody evasion properties of ' 'SARS-CoV-2 Omicron sublineages. Nature. 2022;604:553–6. ' 'https://doi.org/10.1038/s41586-022-04594-4.', 'journal-title': 'Nature.'}, { 'key': '1914_CR27', 'doi-asserted-by': 'publisher', 'unstructured': 'Takashita E, Kinoshita N, Yamayoshi S, et al. Efficacy of antiviral ' 'agents against the SARS-CoV-2 omicron subvariant BA.2. N Engl J Med. ' '2022;386:1475–1477. https://doi.org/10.1056/NEJMc2201933', 'DOI': '10.1056/NEJMc2201933'}, { 'key': '1914_CR28', 'doi-asserted-by': 'publisher', 'unstructured': 'Uraki R, Kiso M, Iida S, et al. Characterization and antiviral ' 'susceptibility of SARS-CoV-2 Omicron/BA.2. Nature. 2022. ' 'https://doi.org/10.1038/s41586-022-04856-1', 'DOI': '10.1038/s41586-022-04856-1'}, { 'key': '1914_CR29', 'doi-asserted-by': 'publisher', 'first-page': '1365', 'DOI': '10.1097/TP.0000000000003670', 'volume': '105', 'author': 'YB Hadi', 'year': '2021', 'unstructured': 'Hadi YB, Naqvi SFZ, Kupec JT, Sofka S, Sarwari A. Outcomes of COVID-19 ' 'in solid organ transplant recipients: a propensity-matched analysis of a ' 'large research network. Transplantation. 2021;105:1365–71. ' 'https://doi.org/10.1097/TP.0000000000003670.', 'journal-title': 'Transplantation.'}], 'container-title': 'Infection', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://link.springer.com/content/pdf/10.1007/s15010-022-01914-8.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://link.springer.com/article/10.1007/s15010-022-01914-8/fulltext.html', 'content-type': 'text/html', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://link.springer.com/content/pdf/10.1007/s15010-022-01914-8.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2022, 9, 9]], 'date-time': '2022-09-09T12:45:17Z', 'timestamp': 1662727517000}, 'score': 1, 'resource': {'primary': {'URL': 'https://link.springer.com/10.1007/s15010-022-01914-8'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2022, 9, 9]]}, 'references-count': 29, 'alternative-id': ['1914'], 'URL': 'http://dx.doi.org/10.1007/s15010-022-01914-8', 'relation': {}, 'ISSN': ['0300-8126', '1439-0973'], 'subject': ['Infectious Diseases', 'Microbiology (medical)', 'General Medicine'], 'container-title-short': 'Infection', 'published': {'date-parts': [[2022, 9, 9]]}, 'assertion': [ { 'value': '7 July 2022', 'order': 1, 'name': 'received', 'label': 'Received', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '25 August 2022', 'order': 2, 'name': 'accepted', 'label': 'Accepted', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '9 September 2022', 'order': 3, 'name': 'first_online', 'label': 'First Online', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, {'order': 1, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Declarations'}}, { 'value': 'The authors declare no competing interests.', 'order': 2, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Competing interests'}}, { 'value': 'The authors have no competing interests as defined by Springer, or other ' 'interests that might be perceived to influence the results and/or discussion ' 'reported in this paper.', 'order': 3, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Conflict of interest'}}, { 'value': 'The study was approved by the central institutional ethics committee (LMU ' 'Munich, Germany; project number 22-0078).', 'order': 4, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Ethical approval'}}]}

Download Image

Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit

Post

@CovidAnalysis

FAQ

Public domain CC0 1.0